Modulation of endothelial cell thrombomodulin by PPAR ligands — variation according to environment
Mangan, Simone, Clancy, Paula, and Golledge, Jonathan (2008) Modulation of endothelial cell thrombomodulin by PPAR ligands — variation according to environment. Thrombosis Research, 121 (6). pp. 827-834.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1016/j.thromres.200...
Introduction: Thrombomodulin (TM) is an important anti-coagulant protein that is down-regulated on endothelial cells overlying atherosclerotic plaques. We investigated the effects of the peroxisome proliferator-activated receptor (PPAR) ligands, fenofibrate and rosiglitazone, on the expression of TM ex vivo by advanced carotid atheromas, and in vitro by endothelial cells.
Methods: Adjacent carotid atheroma biopsies were incubated in vehicle control or PPAR ligand in explant culture for 4 days. Human aortic endothelial cells were incubated with PPAR ligands in vitro. TM expression was measured by Western blotting and flow cytometry. TM activity was assessed by generation of activated protein C.
Results: The PPAR-α activator, fenofibrate, up-regulated total TM expression within carotid explants by 1.7-fold (P < 0.001) with no effect on activity. Rosiglitazone treatment had no effect on protein levels but reduced activity by 73% of the control (P < 0.05). We noted disparate effects of PPAR ligands in atheroma samples from different patients and postulated that the response of endothelial cells to medication was influenced by the atheromatous environment. Incubation of human aortic endothelial cells with fenofibrate alone led to a dose-dependent increase in TM expression (P < 0.05), however, in the presence of oxidized LDL a dose-dependent reduction in TM expression was induced by fenofibrate (P < 0.05).
Conclusions: The ability of fenofibrate to increase endothelial cell and carotid atheroma TM protein expression suggests a potential therapeutic role for this medication. The response to PPAR ligands likely varies depending on the exact constituents of individual atherosclerotic plaques, such as the relative amount of oxidized LDL.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||fenofibrate; rosiglitazone; thrombomodulin; atherosclerosis; endothelial cells|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100%|
|Deposited On:||22 Mar 2010 13:13|
|Last Modified:||18 Oct 2013 00:53|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page